PMC:7461420 / 14934-15174 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T85","span":{"begin":199,"end":206},"obj":"Body_part"}],"attributes":[{"id":"A85","pred":"fma_id","subj":"T85","obj":"http://purl.org/sig/ont/fma/fma82753"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T88","span":{"begin":118,"end":122},"obj":"Disease"}],"attributes":[{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T152","span":{"begin":25,"end":33},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T153","span":{"begin":34,"end":36},"obj":"http://purl.obolibrary.org/obo/CLO_0008337"},{"id":"T154","span":{"begin":101,"end":109},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T155","span":{"begin":144,"end":152},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T156","span":{"begin":226,"end":233},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T157","span":{"begin":234,"end":236},"obj":"http://purl.obolibrary.org/obo/CLO_0008337"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T94","span":{"begin":25,"end":33},"obj":"Chemical"},{"id":"T95","span":{"begin":34,"end":36},"obj":"Chemical"},{"id":"T96","span":{"begin":134,"end":143},"obj":"Chemical"},{"id":"T97","span":{"begin":199,"end":206},"obj":"Chemical"},{"id":"T100","span":{"begin":226,"end":233},"obj":"Chemical"},{"id":"T101","span":{"begin":234,"end":236},"obj":"Chemical"}],"attributes":[{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A95","pred":"chebi_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/CHEBI_35895"},{"id":"A96","pred":"chebi_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A97","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_15428"},{"id":"A98","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_29947"},{"id":"A99","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_57305"},{"id":"A100","pred":"chebi_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A101","pred":"chebi_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/CHEBI_35895"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"504","span":{"begin":118,"end":126},"obj":"Species"},{"id":"509","span":{"begin":199,"end":206},"obj":"Chemical"}],"attributes":[{"id":"A504","pred":"tao:has_database_id","subj":"504","obj":"Tax:694009"},{"id":"A509","pred":"tao:has_database_id","subj":"509","obj":"MESH:D005998"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}